Showing 2671-2680 of 9110 results for "".
The Role of Microneedling in Practice
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-role-of-microneedling-in-practice/18627/Microneedling is gaining in popularity. Amy Forman Taub, MD discusses how she's using microneedling in combination with other treatments like PDT and RF to enhance efficacy and for faster results. She says the number one reason she uses microneedling is for scars. She also cautions on when not to usNewDerm LIVE: Update
https://practicaldermatology.com/topics/practice-management/newderm-live-update/18844/NewDerm LIVE is coming! September 18-20, 2015 at the W Hollywood, CA. Faculty member Neal Bhatia, MD talks to program co-chairs Peter Lio, MD about the goals of the meeting, the agenda, and exciting plans for the weekend. It's not too late to be part of this one-of-a-kind event. Register nowUnderstanding the Effect of Targeting IL-17A/F in Psoriatic Arthritis
https://practicaldermatology.com/programs/practical-dermatology-il-17-journal-club/understanding-the-effect-of-targeting-il-17af-in-psoriatic-arthritis/56663/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Naeim T. Issa, MD, PhD, FAAD, continue their discussion of the Mediterranean Journal of Rheumatology article “Emerging Targets in Psoriatic Arthritis: Dual IL-17A/F and Selective TYK2 Inhibition in a Clinical Perspective,” focusinHow do barrier dysfunction proteins interact with immune dysregulation to sustain AD?
https://practicaldermatology.com/videos/dermatology-hub-neuroimmune-network/how-do-barrier-dysfunction-proteins-interact-with-immune-dysregulation-to-sustain-ad/56736/Raj Chovatiya, MD, PhD, MSCI, FAAD, discusses whether barrier dysfunction drives inflammation and immune dysregulation, or vice versa, or both, in atopic dermatitis.Therapeutic Advances and Fighting for Authorizations
https://practicaldermatology.com/programs/practical-dermatology/therapeutic-advances-and-fighting-for-authorizations/35890/Joel L. Cohen, MD, FAAD, and Leon Kircik, MD, FAAD, discuss the latest developments in psoriasis and atopic dermatitis, as well as the challenges involved with fighting for prior authorizations for the best therapies, at Music City SCALE 2025.Patient Perspectives on Unmet Needs in Topical Psoriasis Therapy
https://practicaldermatology.com/issues/january-february-2025/patient-perspectives-on-unmet-needs-in-topical-psoriasis-therapy/32972/Despite the advantages of topical treatment, nonadherence (including overuse and underuse) affects up to 50% of patients, and therapy overuse is often incited by the desire for rapid clearance, ineffectiveness, and unclear instructions.ASDS: Dr. Downie on Diversity in Dermatology
https://practicaldermatology.com/conferences/asds-2024-annual-meeting/asds-dr-downie-diversity-dermatology/29154/Jeanine B. Downie, MD, FAAD, discusses survey data on different ethnic groups’ cosmetic preferences and the importance of diversity in dermatology at the 2024 American Society for Dermatologic Surgery Annual Meeting.Noah Worcester 2024: Dr. Jogi on Hair Loss
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-jogi-hair-loss/24590/Joel L. Cohen, MD, FAAD, interviews Reena Jogi, MD about her lecture on hair loss and platelet-rich plasma at the 2024 Noah Worcester Dermatological Society meeting.Dupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sThe Menassaince
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-menassaince/18722/Men are an increasingly important demographic in aesthetics today, Steven Dayan, MD tells Dermtube host Joel Cohen, MD. Unlike their female counterparts, men tend to prefer one-and-done procedures and often seek treatment after hours, he says.